Literature DB >> 20510185

Ultrasound dose fractionation in sonodynamic therapy.

Amir H Barati1, Manijeh Mokhtari-Dizaji.   

Abstract

Sonodynamic therapy (SDT) is a new modality in cancer therapy and it is based on preferential uptake and/or retention of a sonosensitizing drug in tumor tissues and subsequent activation of the drug by ultrasound. The dose fractionation effect in radiation therapy has been known for more than a century, but it is not reported in SDT so far. In this study, the in vivo antitumor effect of the simultaneous dual-frequency ultrasound (1 MHz and 150 kHz) at low-level intensity (cumulative I(SATA) = 2.2W/cm(2); total energy density 3960J/cm(2); for 30 min sonication) in combination with the sonosensitizer of photofrin (PF) (sodium porfimer) was investigated in dose fractionation regime in a spontaneous murine model of breast adenocarcinoma in Balb/c mice. The tumor-bearing mice were divided into six groups (n = 8 to 10): Untreated groups included control and sham; experimental groups were treated with 5 mg/kg intravenous injection of PF alone, with combined PF and ultrasound for 30-min sonication in one fraction at 24 h after PF administration; with combined PF and ultrasound for 30 min sonicatin in three fraction at 18, 24 and 30 h after PF administration; and finally with combined PF and ultrasound for 30 min sonication in five fraction at 12, 18, 24, 30 and 36 h after PF administration. The tumor growth delay (TGD) parameters and the percent of apoptotic index AI (%) were measured in treated and untreated groups. The results show that the TGD parameters in treatment groups with combined drug and ultrasound fractionation mode were significantly different compared with other groups (p < 0.05). Also the sonodynamic ultrasound dose fractionation in five fractions is more effective than of the three-fraction regime. The AI of the tumor tissues treated by ultrasound dose fractionation was also significantly higher in the other groups (p < 0.05), in which the AI (%) in the group treated with five fractions was higher with respect to group treated with 3 fractions (11.56 +/- 1.2; 8.7 +/- 0.87), respectively. In conclusion, the ultrasound dose fractionation can be useful in therapeutic effect in SDT and may have future clinical applications. Crown Copyright 2010. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20510185     DOI: 10.1016/j.ultrasmedbio.2010.03.010

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  8 in total

Review 1.  A review of low-intensity ultrasound for cancer therapy.

Authors:  Andrew K W Wood; Chandra M Sehgal
Journal:  Ultrasound Med Biol       Date:  2015-04       Impact factor: 2.998

2.  Comparing the in vivo sonodynamic effects of dual- and single-frequency ultrasound in breast adenocarcinoma.

Authors:  Mahboobeh Alamolhoda; Manijhe Mokhtari-Dizaji; Amir Hoshang Barati; Hadi Hasanzadeh
Journal:  J Med Ultrason (2001)       Date:  2012-03-20       Impact factor: 1.314

3.  Use of a novel sonosensitizer in sonodynamic therapy of U251 glioma cells in vitro.

Authors:  Zhiqiang Chen; Jianhua Li; Xueming Song; Zhi Wang; Wu Yue
Journal:  Exp Ther Med       Date:  2011-11-25       Impact factor: 2.447

Review 4.  Design and Challenges of Sonodynamic Therapy System for Cancer Theranostics: From Equipment to Sensitizers.

Authors:  Zhuoran Gong; Zhifei Dai
Journal:  Adv Sci (Weinh)       Date:  2021-03-12       Impact factor: 16.806

5.  Evaluation of fractionated and repeated sonodynamic therapy by using dual frequency for murine model of breast adenocarcinoma.

Authors:  Mahboobeh Alamolhoda; Manijhe Mokhtari-Dizaji
Journal:  J Ther Ultrasound       Date:  2015-06-24

6.  Sonodynamic effect of hematoporphyrin monomethyl ether on ligature-induced periodontitis in rats.

Authors:  Deshu Zhuang; Jialong Han; Liangjia Bi; Yueping Wang; Yanru Hao; Qi Zhou; Wenwu Cao
Journal:  Drug Des Devel Ther       Date:  2015-05-06       Impact factor: 4.162

7.  Sonodynamic therapy-assisted immunotherapy: A novel modality for cancer treatment.

Authors:  Qianyu Zhang; Cuixia Bao; Xiaojun Cai; Longwei Jin; Lingling Sun; Yuehong Lang; Libo Li
Journal:  Cancer Sci       Date:  2018-05-07       Impact factor: 6.716

Review 8.  Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing.

Authors:  Tianxu Fang; Xiaona Cao; Mysha Ibnat; Guojun Chen
Journal:  J Nanobiotechnology       Date:  2022-08-02       Impact factor: 9.429

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.